Arizona Accuses Insys of Fraudulent Opioid Marketing Scheme


Arizona accuses Insys of fraudulent opioid marketing scheme

Insys did not immediately respond to a request for comment. Lawyers for the three doctors – Steve Fanto, Nikesh Seth and Sheldon Gingerich – couldn’t be identified.

The lawsuit accused of paying doctors sham speaker fees in exchange for writing prescriptions of Subsys Insys.

“We will need to put a stop to the unethical and greedy behavior in the pharmaceutical industry that is fueling the opioid crisis in our state,” Brnovich said in a statement.

Babich and his co-defendants have pleaded not guilty. Federal charges have been filed in several different states against other ex-Insys employees and professionals who prescribed Subsys.
The case is the latest to center on Subsys, opioid that is regulated, an extremely addictive and an spray intended for cancer patients which contains fentanyl.

(Reuters) – Arizona’s attorney general sued Insys Therapeutics Inc on Thursday, accusing the drugmaker of engaging in a fraudulent marketing strategy aimed at increasing sales of a fentanyl-based cancer pain medicine.

Three Arizona doctors were also named by the lawsuit while writing as defendants who it said speaker fees that were collected from Insys.
Insys has said it’s in discussions with the U.S. Justice Department to solve the federal probe.
Reporting by Nate Raymond in Boston; Editing by Lisa Von Ahn

The lawsuit by Arizona Attorney General Mark Brnovich in Maricopa County Superior Court in Phoenix comes through a series of national and state investigations based on Insys’ Subsys opioid drug.

Federal prosecutors in Boston charged managers and six former Insys executives, including ex-Chief Executive Michael Babich, with engaging in a scheme to bribe doctors to prescribe Subsys.